DexcomDXCM.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, Dexcom (DXCM.O) trades at a P/E of 32.50x, P/B of 12.40x, P/S of 6.53x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 10th percentile over the trailing 10Y window (vs. 22nd percentile over 3Y); P/B sits at the 16th percentile over the trailing 10Y window (vs. 46th percentile over 3Y); P/S sits at the 12th percentile over the trailing 10Y window (vs. 35th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 65th percentile within its industry and the 73rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.54%, ranking at the 89th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 6.6 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Dexcom operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: DXCM · DXCM
Want the full picture on whether Dexcom (DXCM.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 32.50 | ||||||
| P/B (MRQ) | 12.40 | ||||||
| P/S (TTM) | 6.53 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 1.54% |